Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Accumulated Expenses (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Other Accumulated Expenses data on record, last reported at $394000.0 in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 58.17% year-over-year to $394000.0; the TTM value through Dec 2025 reached $394000.0, down 58.17%, while the annual FY2025 figure was $394000.0, 58.17% down from the prior year.
  • Other Accumulated Expenses reached $394000.0 in Q4 2025 per CLDX's latest filing, down from $930000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.6 million in Q1 2021 and bottomed at $283000.0 in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 296.42% in 2024, then plummeted 74.68% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $283000.0 in 2021, then rose by 13.07% to $320000.0 in 2022, then rose by 18.12% to $378000.0 in 2023, then skyrocketed by 149.21% to $942000.0 in 2024, then plummeted by 58.17% to $394000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $394000.0 in Q4 2025, $930000.0 in Q3 2025, and $930000.0 in Q2 2025.